Purging disorder

Lieff Cabraser and Protectus Law Announce Filing of Lawsuit on Behalf of Utah Teen with Anorexia Against Instagram/Meta/Facebook

Retrieved on: 
星期二, 九月 6, 2022
Class Action Lawsuit, Professional Services, Legal, Complaint, Advertising, Meta, LLP, Death, Mark (given name), Pressure, Anxiety, Adolescence, Purging disorder, Depression, Self-control, Mental health, Failure, Health, Lists of diseases, Social media, Birth control, Instagram

When we read the account of the whistleblower that Facebook/Instagram was deliberately targeting young teenagers with its harmful design, we were horrified.

Key Points: 
  • When we read the account of the whistleblower that Facebook/Instagram was deliberately targeting young teenagers with its harmful design, we were horrified.
  • "Instagram has profited off of young peoples vulnerabilities for long enough," notes Lieff Cabraser partner Lexi Hazam, who represents the plaintiffs in the case.
  • "There are roughly 160 million Instagram users in the U.S.," notes Protectus Law partner Neal Roberts, who also represents the plaintiffs in the suit.
  • Roughly two in five teen users reported feeling unattractive, while one in ten teen users reporting suicidal thoughts traced them to Instagram.

Monte Nido & Affiliates to Open their first Residential Eating Disorder Program in Cherry Hill, NJ

Retrieved on: 
星期二, 八月 23, 2022
Mortality, Clementine, Anorexia nervosa, Program, Doctor of Philosophy, Purging disorder, Joint Commission, Exercise addiction, Diagnosis, Adolescence, Rosewood Center, Eating disorder, Binge eating disorder, MS, LMHC, Network affiliate, Lists of diseases, Medicine

CHERRY HILL, N.J., Aug. 23, 2022 /PRNewswire/ -- Monte Nido & Affiliates, one of the largest and leading eating disorder platforms in the country, announces the upcoming opening of a new residential eating disorder center in Cherry Hill, New Jersey. Opening in late 2022, Clementine Cherry Hill will provide care for adolescents of all genders with anorexia nervosa, bulimia nervosa, binge eating disorder and/or exercise addiction. Clementine Cherry Hill will be the company's first program in New Jersey as it expands to its 15th state.

Key Points: 
  • CHERRY HILL, N.J., Aug. 23, 2022 /PRNewswire/ -- Monte Nido& Affiliates , one of the largest and leading eating disorder platforms in the country, announces the upcoming opening of a new residential eating disorder center inCherry Hill, New Jersey.
  • Clementine Cherry Hill will be the company's first program in New Jersey as it expands to its 15th state.
  • Monte Nido& Affiliates is one of the country's largest and leading eating disorder platforms, offering inpatient, residential, and day treatment programs for eating disorders.
  • Founded in 1996,Monte Nido& Affiliates currently operates programs in fourteen states, with residential programs being Joint Commission accredited.Monte Nido& Affiliates includes five distinct eating disorder program brands:Monte Nido, Walden Behavioral Care, Rosewood Centers,Oliver-Pyatt Centers, and Clementine.

Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5

Retrieved on: 
星期二, 八月 16, 2022
Cortex, U.S. Securities and Exchange Commission, Securities Act of 1933, University, Cerebral cortex, Inflammation, Industry, Stony Brook University, GLOBE, Peripheral neuropathy, Cancer, Brain, Fear, Securities Exchange Act of 1934, Purging disorder, Security (finance), Research, Pain, Post-traumatic stress disorder, FABP5, Doctor of Philosophy, Lipid, Twitter, Cannabinoid, CB2, Anxiety, Nature, Neuroscience, Lead, FABP, Protein, Private Securities Litigation Reform Act, Screen for child anxiety related disorders, Diathesis–stress model, Nasdaq, PTSD, Organic acid, Pharmaceutical industry

President and Chief Executive Officer of Artelo Biosciences.

Key Points: 
  • President and Chief Executive Officer of Artelo Biosciences.
  • This new data further supports the development of our FABP inhibitor platform in anxiety-related disorders such as post-traumatic stress disorder.
  • We are encouraged by these findings which indicate inhibiting FABPs represents a promising neurobiological approach for the development of novel anxiety-inhibiting pharmacotherapies.
  • Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions.

SHORT WAVE PHARMA SIGNS CLINICAL TRIAL AGREEMENT WITH THE SHEBA RESEARCH FUND AND THE SHEBA CENTER FOR EATING DISORDERS

Retrieved on: 
星期一, 八月 15, 2022
Death, Purging disorder, Movement, Anorexia nervosa, Risk, Chronic pain, Trial, Fund, Lists of diseases, Population, Shortwave broadband antenna, Incidence, Disability, Eating disorder, Suicide, Drama, Clinical trial, Method, Psilocybin, The Company, Patient, Company, Program, Ministry, Health care, Safety, Drug development, Neurodegeneration, Binge eating disorder, Physician, Conditional sentence, API, Agreement, Social, Shortwave radio, The Trial, Metabolism, Pharmaceutical industry, Residential care, Health, Research

The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.

Key Points: 
  • The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.
  • Anorexia nervosa is a life-threatening disease and a severe eating disorder that affects about 0.5-1% of the population.
  • Shortwave's leadership team combines years of experience in drug development and clinical research, accelerated regulatory pathways and pharmaceutical industry expertise.
  • As Israel's top facility for treating eating disorders, it strives to address the need for safe and effective novel treatments.

Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
星期二, 八月 9, 2022
U.S. Securities and Exchange Commission, GLOBE, Cancer, Investment, Toxicity, Board, Purging disorder, AstraZeneca, Security (finance), Pain, Peripheral neuropathy, Patient, Appetite, Securities Act of 1933, Securities Exchange Act of 1934, Immune system, Inflammation, Industry, FABP5, Lipid, Cannabinoid, Șaeș, CB2, Nature, Board of directors, CB1, Nasdaq, Weight loss, Pharmacokinetics, Anorexia nervosa, Human, Compliance, 8-K, Radiation, Dehydration, Reverse stock split, Anxiety, FABP, Organic acid, RATS, Review, Oxaliplatin, Company, Twitter, Weight gain, Therapy, Protein, Private Securities Litigation Reform Act, Online gambling, Pharmaceutical industry

SOLANA BEACH, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating results for the three months ended June 30, 2022.

Key Points: 
  • The Companys common shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open, August 10, 2022.
  • For further details, all shareholders are invited to review the 8-K regarding this reverse split filed today, August 9, 2022.
  • Financial Results Ended June 30, 2022
    Operating expenses for the three months ended June 30, 2022, were $2.4 million compared to $2.3 million for the same period in 2021.
  • Artelo Biosciences, Inc.is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system.

COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa

Retrieved on: 
星期四, 七月 28, 2022
Lists of diseases, King's College London, Osteoporosis, Brain, Psychiatry, Columbia University Irving Medical Center, University, Education, Mortality, EDE, TRD, Research, Anorexia nervosa, Food, Woman, History, Purging disorder, Interview, CMPS, Safety, Eating Disorder Examination Interview, Seizure, Clinical trial, Suicide, UC San Diego School of Medicine, Mental health, US Food Sovereignty Alliance, University College London Hospitals NHS Foundation Trust, FDA, COMPASS, Patient, Nasdaq, Death, Man, Face, Heart failure, IIB, Sheppard and Enoch Pratt Hospital, Columbia University, Principal investigator, Pharmaceutical industry

Research and progress are urgently needed; weve already seen encouraging data from an exploratory, open-label study in treating anorexia nervosa with COMP360 psilocybin therapy, and this phase II study represents another important step forward.

Key Points: 
  • Research and progress are urgently needed; weve already seen encouraging data from an exploratory, open-label study in treating anorexia nervosa with COMP360 psilocybin therapy, and this phase II study represents another important step forward.
  • We are conducting this rigorous clinical trial to understand whether COMP360 psilocybin, with psychological support, could help people living with anorexia nervosa who urgently need new options."
  • This will be the first study to use myPathfinder, COMPASS digital application for supporting patients throughout their COMP360 psilocybin therapy journey.
  • We are also running a phase II clinical trial of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD).

Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

Retrieved on: 
星期二, 七月 19, 2022
Dehydration, AstraZeneca, Cancer, Patient, Security (finance), Nasdaq, Pharmacokinetics, Safety, Weight loss, U.S. Securities and Exchange Commission, CB1, Therapy, Inflammation, GLOBE, Private Securities Litigation Reform Act, CB2, Securities Exchange Act of 1934, United, Twitter, Immune system, Weight gain, Peripheral neuropathy, Anxiety, Securities Act of 1933, Purging disorder, Industry, Company, Pain, Human, Drug Quality and Security Act, Appetite, Anorexia nervosa, Radiation, Nature, Toxicity, Pharmaceutical industry

Furthermore, we have seen pharmacokinetics consistent with the AstraZeneca experience and an improvement in anorexia from each dose escalation.

Key Points: 
  • Furthermore, we have seen pharmacokinetics consistent with the AstraZeneca experience and an improvement in anorexia from each dose escalation.
  • The Cancer Appetite Recovery Study (CAReS) is a Phase 1b/2a randomized, placebo-controlled trial of the Companys lead clinical program, ART27.13, in patients with cancer anorexia and weight loss.
  • Anorexia, or the lack or loss of appetite in cancer patients, may result from the cancer and/or its treatment with radiation or chemotherapy.
  • Anorexia and the resulting weight loss can affect a patients health, often weakening their immune system and causing discomfort and dehydration.

Elanco Survey Finds Many Pets Live Unprotected Against Preventable Diseases

Retrieved on: 
星期二, 七月 12, 2022
General Health, Health, Pets, Consumer, Prevalence, Disease, Infection, Purging disorder, Society, Multimedia, Animal, Vaccine, ASPCA, Leptospirosis, Awareness, Veterinarian, Risk, Gaps, Name, ELAN, Adult, COVID-19, Savanta ComRes, Depression, Interpersonal relationship, PETS, Dog, Symptoms of COVID-19, Soil, Health, Vomiting, NYSE, Pet, Vaccination, Water, Lethargy, Farmer, Parent, Pharmaceutical industry, Lyme disease, Food, Elanco

Amidst a surge of pet adoptions, a new survey released by Elanco finds many pets are insufficiently protected against common diseases like Lyme and leptospirosis.

Key Points: 
  • Amidst a surge of pet adoptions, a new survey released by Elanco finds many pets are insufficiently protected against common diseases like Lyme and leptospirosis.
  • At Elanco, we believe vaccinated pets are the happiest pets.
  • Pets and parents share a unique and loving bond and our goal is to make sure pets live longer, healthier lives.
  • ASPCA Pandemic Pet Ownership Survey Memo, May 2021
    Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

Romidepsin for Injection Available from Fresenius Kabi

Retrieved on: 
星期二, 七月 12, 2022
Oncology, Medical Supplies, Health, Medical Devices, General Health, Pharmaceutical, Biotechnology, DNA virus, Infection, Nausea, Purging disorder, Thrombocytopenia, HDAC, T-cell lymphoma, Itch, INR, LLC, Birth, Neutropenia, Multimedia, Anemia, Potassium, History, CYP3A4, Risk, Hepatitis B, Patient, CEO, ECG, Fetus, Adult, Tumor lysis syndrome, Hepatitis, Cardiovascular disease, Leukopenia, CTCL, Injection, Pulmonary toxicity, Rifampicin, Toxicity, DNA, Fresenius (company), Lymphocytopenia, Fatigue, Warfarin, FDA, Magnesium, Constipation, Vomiting, Cancer, Prothrombin time, Female, Pharmaceutical industry, Vaccine, Medical imaging, Birth control, Romidepsin, Dysgeusia

Fresenius Kabi announced today the immediate availability in the United States of Romidepsin for Injection, the newest addition to the companys broad portfolio of injectable oncology medicines.

Key Points: 
  • Fresenius Kabi announced today the immediate availability in the United States of Romidepsin for Injection, the newest addition to the companys broad portfolio of injectable oncology medicines.
  • View the full release here: https://www.businesswire.com/news/home/20220712005418/en/
    Fresenius Kabi Romidepsin for Injection is the first approved generic equivalent for ISTODAX, providing clinicians and patients with a more affordable treatment option.
  • (Photo: Business Wire)
    Fresenius Kabi Romidepsin for Injection is the first approved generic equivalent for ISTODAX, providing clinicians and patients with a more affordable treatment option.
  • Fresenius Kabi Romidepsin is supplied as a kit including one 10 mg single-dose vial of Romidepsin and one 2.2 mL vial of diluent.

Arise Raises Over $4 Million to Build Inclusive Eating Disorder Treatment and Mental Health Support

Retrieved on: 
星期一, 七月 11, 2022
People, Anxiety, BIPOC, Health, Language, Greycroft, Solution, Microdeletion syndrome, COVID-19, Purging disorder, PTSD, Man, Medicaid, Eating disorder, Body image, Mental health, Personality disorder, Depression, Binge eating disorder, MPH, NEW, Lists of diseases, Trauma, ARFID, Food, Opioid use disorder, Coffee, Health insurance, City block, MD

NEW YORK, July 11, 2022 /PRNewswire/ -- Arise, the digital healthcare company enabling comprehensive care for eating disorders, mental health, and long-term healing, has launched today after raising over $4 million in a seed funding round. Arise is building a virtual-first care model to reach and engage more of the 30 million Americans who will experience an eating disorder in their lifetime — 80-90% of whom will not get care today. The round was led by Greycroft and BBG Ventures with participation from Wireframe Ventures, Cityblock co-founder Iyah Romm (he/him) and Sonder Health founder Sylvia Romm, MD, MPH (she/her), and PatientPing founder Jay Desai (he/him), among others.

Key Points: 
  • Arise is building a virtual-first care model to reach and engage more of the 30 million Americans who will experience an eating disorder in their lifetime 80-90% of whom will not get care today.
  • Arise will bring integrated community and clinical care to people living with disordered eating and eating disorders, which are a category of conditions that can show up in different ways for people including binge eating disorder, bulimia, anorexia, rumination disorder, avoidant or restrictive food intake disorder (ARFID), and other conditions.
  • Stigma makes it difficult for people to identify their eating disorder and this is magnified when your families and communities don't have language to describe, let alone identify, the eating disorder.
  • Arise launches at a time when eating disorders, which are the second deadliest behavioral health condition after opioid use disorder, are sharply increasing.